Did You Know...
...that the inventor of the electric motor was a blacksmith named Thomas Davenport? Described as "a brilliantly unsuccessful inventor", Davenport invented the first rotary electric motor. In 1836 he headed out -- on foot -- from his Vermont home to file a patent application at the Patent Office in Washington, D.C. By the time he got there, he had squandered away his money and couldn't afford the $30 filing fee so he turned around and went home. When he later mailed in his application with money he'd raised, the Patent office was destroyed in a fire. He did finally get credit for his invention on Feb. 5, 1837.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8110719 | ABI1 conditional knockout mouse Genetically engineered conditional knock-out mice having conditional disruption of the Abi1/Hssh3bp1 gene are disclosed along with methods of making and using same. ... | 02/07/2012 |
| 8110720 | Transgenic mice expressing humanized VEGF The present invention generally relates to humanized VEGF and non-human transgenic animals expressing it. The transgenic animals are also useful to study VEGF-related therapies. ... | 02/07/2012 |
| 8101816 | RGMc modified transgenic animals The invention provides a new reproducible transgenic mouse model for the study of iron accumulation in the body. In particular, the invention concerns the study of iron overload in an RGMc knockout mouse model and its use in drug discovery and research. ... | 01/24/2012 |
| 8076532 | Transgenic mouse defective in WW45 function and use in screening compounds for anti-tunour activity Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms w... | 12/13/2011 |
| 8071839 | Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use The present invention relates to transgenic non-human mammals comprising a polynucleotide encoding a human or humanized C5aR. The invention also relates to use of the transgenic non-human mammals in methods of screening for agonists, inverse agonists and antagonists... | 12/06/2011 |
| 8067666 | Model animal causing the white hair development and methods relating thereto A model rodent animal with a phenotype in which hair growing after birth is black, with the animal spontaneously developing white hair after aging. By way of example, the model rodent animal may have a genotype in which an activated RET gene is genetically inserted ... | 11/29/2011 |
| 8022268 | Transgenic animal model for alzheimer's disease Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyl... | 09/20/2011 |
| 8008539 | Generation of transgenic human soluble amyloid precursor protein alpha expressing mice The present invention relates to a novel animal model for neurological degenerative diseases, especially autism, relating to overexpression of human secreted APP-alpha. This novel animal model exhibits several aspects of amyloidopathy. The present invention also rel... | 08/30/2011 |
| 7968762 | Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF) A transgenic animal model for evaluating growth, survival and/or metastasis of xenotransplanted normal or tumor cells or tissue is disclosed, in which a human growth factor, hHGF stimulates growth in vivo of human cells or tissue. A strain of Tg mice on the C3H back... | 06/28/2011 |
| 7964767 | Transgenic mice expressing baculovirus soluble GP64 and methods of using such mice to make antibodies Membrane proteins that are background antigens were solubilized, and transgenic animals were produced using genes encoding these soluble proteins. Antibodies against the background antigen membrane proteins comprised in the immunogens were not found in these transge... | 06/21/2011 |
| 7943815 | Transgenic mouse for screening and for studies of the pharmacodynamics and pharmacokinetics of ligands acting on the oestrogen receptor and its intracellular receptors, and method for the preparation thereof The object of the invention is a method for the production of a non-human transgenic mammal by means of which it is possible to monitor in vivo and in all the tissues the state of activation of any intracellular receptor, utilizing a reporter gene inducible by natur... | 05/17/2011 |
| 7932431 | Genetically modified non-human mammals and cells A genetically modified non-human mammal or cell characterised in that it does not comprise a nucleic acid sequence which itself encodes any endogenous immunoglobulin heavy chain constant region locus polypeptide. ... | 04/26/2011 |
| 7919674 | Transgenic mammal carrying GANP gene transferred thereinto and utilization thereof It is an object of the present invention to provide a high affinity antibody effective as a diagnostic or therapeutic for various diseases; a transgenic mammal for producing the high affinity antibody; and a medicine comprising the high affinity antibody or a cell p... | 04/05/2011 |
| 7910798 | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies The invention provides transgene constructs for expressing chimeric antibodies, and transgenic non-human host animals carrying such constructs, wherein the chimeric antibodies comprise human variable regions and constant regions of the non-human transgenic host anim... | 03/22/2011 |
| 7868223 | Method for modifying chromosomes The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chro... | 01/11/2011 |
| 7847148 | Oasis gene-deficient mouse A mouse that is deficient in the function of the gene for OASIS, and a method for screening for, or evaluating a pharmacological efficacy of, therapeutic agents for osteoporosis using the mouse. ... | 12/07/2010 |
| 7834238 | Saspase knockout animal Knockout animals in which a gene encoding a SASPase has been deleted (hereinafter, referred to as SASPase KO animals) are provided. The SASPase KO animals deficient in expression of functional SASPase were produced by deleting a gene encoding a stratified epithelium... | 11/16/2010 |
| 7834237 | Materials and methods relating to protein aggregation in neurodegenerative disease Disclosed is a method of inducing or modeling a disease associated with pathological tau protein aggregation. The method can be carried out in vitro and animal models, and may be used to screen for therapeutic, prognostic or diagnostic agents. ... | 11/16/2010 |
| 7820876 | Mouse mutant for expression of the alpha6 subunit of the nicotinic acetylcholine receptor The invention concerns a non-human mammal carrying a mutation in the gene coding for the alpha6 subunit of the nicotinic acetylcholine receptor (nAChR), said mutation preventing expression of said nAChR alpha6 subunit in a functional form in the mammal. The i... | 10/26/2010 |
| 7820877 | Transgenic mammals having human IG loci including plural Vand Vregions and antibodies produced therefrom The present invention relates to transgenic non-human animals that are engineered to contain human immunoglobulin gene loci. In particular, animals in accordance with the invention possess human Ig loci that include plural variable (VH and Vκ) gene regio... | 10/26/2010 |
| 7807864 | Transgenic animal as a model for fibrotic diseases Disclosed is a transgenic non-human animal with broad or cell type-specific ectopic expression of fra-2 that manifests itself in a fibrotic disease, methods for obtaining such animal and their use. Fra-2 transgenic animals, in particular mice, are useful as model sy... | 10/05/2010 |
| 7803982 | T1R3 transgenic animals, cells and related methods The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses ... | 09/28/2010 |
| 7795495 | Transgenic mice for screening for inhibitors of protein aggregation and methods for making and using them The methodologies of the present invention demonstrate that a critical balance between pro- and anti-amyloidogenic molecules exists that regulates amyloid formation and cell death in Alzheimer's disease and Parkinson's disease. β-Synuclein, the non-amyloidogenic ho... | 09/14/2010 |
| 7795494 | Transgenic mice expressing antibodies specific for genes of interest and uses thereof The invention provides compositions and methods for the generation of novel non-human transgenic animals which contain an alteration in a gene of interest. These transgenic animals are capable of generating antibodies, e.g., human monoclonal antibodies, specific for... | 09/14/2010 |
| 7767881 | Utilization of histamine receptor h3 gene participating in body weight or food intake control To clarify histamine receptor H3 protein function in vivo, the present inventors constructed a nonhuman higher animal in which the expression of a histamine receptor H3 gene was artificially inhibited. As a result, the present inventors found that this nonhuman high... | 08/03/2010 |
| 7759542 | Glycine N-methyltransferase (GNMT) animal model and use thereof The present invention is a new type of Glycine N-methyltransferase (GNMT) knockout mice model. This model can be applied to screen drug, test of treatment and search for diagnostic marker of hepatocellular carcinoma (HCC), glycogen storage disease, liver dysplasia, ... | 07/20/2010 |
| 7759541 | Transgenic animals for assessing drug metabolism and toxicity The present invention relates to transgenic non-human animals, tissues or cells derived therefrom and methods of producing them. The transgenic non-human animals or tissues or cells derived therefrom provide a system capable of expressing human proteins responsible ... | 07/20/2010 |
| 7745690 | Transgenic nonhuman mammal representing the pathologic conditions of human rheumatoid arthritis It is intended to provide a transgenic nonhuman mammal well representing the pathologic conditions of human rheumatoid arthritis. A transgenic nonhuman mammal is obtained by transferring a foreign DNA, wherein a DNA selected from the group consisting of an MHC class... | 06/29/2010 |
| 7745691 | Genetically modified mouse lacking diacylglycerol acyltransferase-1 (DGAT-1) activity Methods and compositions for modulating carbohydrate metabolism in a host are provided. In the subject methods, diacylglycerol acyltransferase (DGAT) activity (specifically DGAT1 activity) is modulated, e.g., reduced or enhanced, to achieve a desired insulin and/or ... | 06/29/2010 |
| 7741529 | Transgenic animal model for catecholaminergic polymorphic ventricular tachycardia (CPVT) and use thereof The present invention refers to non-human transgenic mammals, preferably rodents, or mice, which comprise a mutation in the gene encoding for the cardiac ryanodine receptor (RyR2). Transgenic animals carrying the amino acid change R4496C in the RyR2 protein s... | 06/22/2010 |
| 7732658 | Composition and method for imaging cells The invention relates to compositions containing a polynucleotide encoding for a reporter gene, a selectable marker and a regulatory element, that provide a method for imaging cells in vivo. ... | 06/08/2010 |
| 7728189 | Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression Transgenic animals containing a nucleic acid sequence encoding TCL1 operably linked to transcriptional control sequences directing expression to B cells are described. Such transgenic animals provide a useful animal model system for human B cell chronic lymphocytic ... | 06/01/2010 |
| 7723564 | Compositions and methods for modulation of KSR1 and KSR2 interactions Materials and methods for identifying agents which modulate KSR mediated signal transduction are provided. ... | 05/25/2010 |
| 7709695 | Transgenic mouse expressing arctic mutation E693G A transgenic non-human animal expressing at least one transgene including a DNA sequence encoding a heterologous Amyloid Precursor Protein (APP) including at least the Arctic mutation (E693G) and a further AD (Alzheimer's disease) pathogenic mutation or a further tr... | 05/04/2010 |
| 7705199 | Compositions and methods for treatment of autoimmune and related diseases Compositions and methods are provided for treatment of autoimmune and other related diseases. 3d, a point mutation of the protein uncoordinated-93b (unc-93B), unc-93A, unc-93B, and unc-93C, polypeptides, nucleic acids encoding them and methods for making and using t... | 04/27/2010 |
| 7705198 | KSR2 knockout mice and methods of use thereof A transgenic non-human animal with a homologous disruption of the KSR-2 gene is disclosed. Methods for using transgenic mice so generated to screen for agents that effect cellular metabolism are also provided. ... | 04/27/2010 |
| 7700823 | Transgenic animals exhibiting major disorders related to Alzheimer's disease The present invention relates to nonhuman transgenic animals exhibiting major disorders related to Alzheimer's disease. The animals can be used for demonstrating compounds intended for the treatment of Alzheimer's disease. ... | 04/20/2010 |
| 7700824 | Methods A non-human animal which has a reduced amount of functional TAZ polypeptide and/or TAZ-like polypeptide, or a reduced amount of nucleic acid encoding said polypeptide. A method for generating a non-human animal which develops PKD comprising reducing the amount of fu... | 04/20/2010 |
| 7667090 | Transgenic mouse model of B cell malignancy A transgenic non-human animal, such as a mouse, has a genome that include a nucleic acid construct having at least one transcriptional regulatory sequence capable of directing expression in B cells of the animal, wherein the transcriptional regulatory sequence is op... | 02/23/2010 |
| 7659441 | CD9/CD81 double-deficient non-human animal An object of the invention is to provide a non-human animal which can be utilized as a model animal well exhibiting a pathological condition of low-turnover type of osteoporosis and chronic obstructive pulmonary disease, for screening therapeutic agents for osteopor... | 02/09/2010 |
